Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., has announced the FDA approval of its new CardioGen-82 infusion system to enhance automation, efficiency and simplicity in cardiac position emission tomography (PET) myocardial perfusion imaging (MPI). This next-generation infusion system model will replace the company’s current infusion system.
Vittorio Puppo, president and CEO of Bracco Diagnostics Inc., said, “The new infusion system exemplifies Bracco’s significant investment in the cardiac PET imaging modality and is the culmination of thoughtful design and feedback from health care providers. Developing innovative products that support clinicians in diagnosing coronary artery disease is our commitment to the patients we serve.”
Developed with clinicians and nuclear medicine technologists in mind, the new infusion system is elegantly designed with intuitive and ergonomic details that provide easy access to all system components while minimizing radiation exposure for staff and patients.
Other smart features enable workflow efficiencies that can save nearly an hour at the beginning of each day of patient imaging and eliminate manual record keeping. A choice of dosing options and other protocol parameters make changes in scheduling and patient needs easy to accommodate.
“Cardiac PET MPI with the CardioGen-82 generator has helped accurately diagnose thousands of patients since 1989,” said Kim McDaniel, senior director, nuclear medicine sales and market support. “Bracco was the first company to heavily invest in the modality for the diagnosis of coronary artery disease, and our introduction of the new infusion system is one more example of our commitment to our customers and patients worldwide.”
See full Prescribing Information for CARDIOGEN-82 (Rubidium Rb 82 Generator) including boxed WARNING at https://imaging.bracco.com/us-en/products/nuclear-medicine-radiopharmaceuticals/cardiogen-82.
For additional information, visit imaging.bracco.com/us-en.